FDA Regulatory Affairs Head Glavin Makes Retooling Of Field Force A Priority
Executive Summary
Management of FDA's field resources will be a top priority for Associate Commissioner for Regulatory Affairs Margaret Glavin as she undertakes a wide-ranging review of office practices
You may also be interested in...
FDA Rx Safety Website Will Include Drugs With Emerging Off-Label Issues
FDA's "Drug Watch" website will include safety information on drugs that have emerging safety signals for off-label uses
FDA Will Fund Research On “Critical Path” Of Drug Development
FDA's "Critical Path" initiative will redirect the agency's research funding towards identifying and alleviating some major barriers to drug development
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011